GemPharmatech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	830.61	793.39	686.28	621.73	515.67	392.44
Other Revenue	-	-	0.56	0.45	0.87	1.34
Revenue	830.61	793.39	686.84	622.19	516.55	393.79
Revenue Growth (YoY)	18.56%	15.51%	10.39%	20.45%	31.17%	50.35%
Cost of Revenue	296.08	284.43	261.33	202.86	150.22	101.27
Gross Profit	534.53	508.96	425.51	419.33	366.33	292.51
Selling, General & Admin	249.4	246.04	239.68	199.61	174.76	134.42
Research & Development	93.67	92.06	87.13	96.6	82.93	55.2
Other Operating Expenses	-9.54	-11.12	3.57	2.61	1.72	1.59
Operating Expenses	333.53	326.97	333.68	307.91	267.94	196.11
Operating Income	201	181.99	91.83	111.42	98.39	96.4
Interest Expense	-0.61	-	-4.3	-2.76	-0.5	-0.74
Interest & Investment Income	16.67	8.75	22.39	28.65	23.73	14.43
Currency Exchange Gain (Loss)	-	-	1.69	0.08	1.49	-0.19
Other Non Operating Income (Expenses)	-11.56	-6.7	-21.56	-20.92	-11.32	-16.05
EBT Excluding Unusual Items	205.5	184.04	90.06	116.48	111.8	93.84
Gain (Loss) on Sale of Investments	0.02	0.69	2.34	2.73	-0.05	0.32
Gain (Loss) on Sale of Assets	0.02	-0.04	0.01	-0.02	-0.1	0.05
Asset Writedown	-17.74	-19.77	-	-	-	-
Other Unusual Items	-	-	26.8	42.1	62.03	49.1
Pretax Income	187.8	164.92	119.22	161.29	173.68	143.31
Income Tax Expense	28.04	22.29	9.4	2.37	9.02	18.39
Earnings From Continuing Operations	159.76	142.64	109.82	158.91	164.67	124.93
Net Income	159.76	142.64	109.82	158.91	164.67	124.93
Net Income to Common	159.76	142.64	109.82	158.91	164.67	124.93
Net Income Growth	44.81%	29.88%	-30.89%	-3.49%	31.81%	63.45%
Shares Outstanding (Basic)	399	408	407	407	392	357
Shares Outstanding (Diluted)	399	408	407	407	392	357
Shares Change (YoY)	-2.43%	0.19%	-0.18%	3.93%	9.84%	-1.93%
EPS (Basic)	0.40	0.35	0.27	0.39	0.42	0.35
EPS (Diluted)	0.40	0.35	0.27	0.39	0.42	0.35
EPS Growth	48.42%	29.63%	-30.77%	-7.14%	20.00%	66.67%
Free Cash Flow	161.38	122.04	-23.36	-89.33	-84.33	24.24
Free Cash Flow Per Share	0.41	0.30	-0.06	-0.22	-0.21	0.07
Dividend Per Share	-	-	0.140	0.160	0.041	-
Dividend Growth	-	-	-12.50%	290.24%	-	-
Gross Margin	64.35%	64.15%	61.95%	67.40%	70.92%	74.28%
Operating Margin	24.20%	22.94%	13.37%	17.91%	19.05%	24.48%
Profit Margin	19.23%	17.98%	15.99%	25.54%	31.88%	31.72%
Free Cash Flow Margin	19.43%	15.38%	-3.40%	-14.36%	-16.33%	6.16%
EBITDA	276.71	257.11	164.62	157.42	135.68	125.2
EBITDA Margin	33.31%	32.41%	23.97%	25.30%	26.27%	31.80%
D&A For EBITDA	75.71	75.12	72.79	46	37.29	28.81
EBIT	201	181.99	91.83	111.42	98.39	96.4
EBIT Margin	24.20%	22.94%	13.37%	17.91%	19.05%	24.48%
Effective Tax Rate	14.93%	13.51%	7.88%	1.47%	5.19%	12.83%
Revenue as Reported	37.22	-	686.84	622.19	516.55	393.79
Advertising Expenses	-	-	2.93	4.69	8.94	2.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.